Atopic dermatitis (AD) is a chronic inflammatory disease of the skin. It affects around 15-20% of children and 1-3% of adults. Almost 19% of children do not respond to current treatments.
According to WHO the Quality of Life (QoL) impacts on children with Atopic Dermatitis are second only to Cerebral Palsy amongst childhood disorders.
Atopic Dermatitis happens when the body loses control over the Innate Immune System, an ancient immune mechanism design to protect our skin from bacterial and parasitic attacks.
ILC Therapeutics™ have developed and patented a number of synthetic peptides shown to powerfully modulate the key cells involved in Atopic Dermatitis.
Our research and drug candidates represent a paradigm shift in Atopic Dermatitis treatment modulating the very earliest parts of the ongoing immune response. An analogy would be : putting out
the camp fires before they spread and become significant life changing forest fires.
Basophils, Eosinophils & ILC 2 Effects
Our lead peptide ILCT 1001 has been shown to:
Significantly downregulate (x100’s fold) the expression of IgE receptors on Basophils.
Reduce the production of IL-5 an Eosinophil growth factor and key player in allergic reactions.
Reduce IL-4 production an Eosinophil attractant.
Reduce IL-13 production.